Assembly Biosciences Files 2024 10-K, Cites Gilead Deal
Ticker: ASMB · Form: 10-K · Filed: Mar 20, 2025 · CIK: 1426800
| Field | Detail |
|---|---|
| Company | Assembly Biosciences, INC. (ASMB) |
| Form Type | 10-K |
| Filed Date | Mar 20, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceuticals, partnership, equity-agreement
TL;DR
ASMB 2024 10-K out. Mentions microbiome deal & Gilead equity. Check financials.
AI Summary
Assembly Biosciences, Inc. filed its 2024 10-K on March 20, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly known as Ventrus Biosciences Inc., is focused on pharmaceutical preparations. Key events and agreements mentioned include a microbiome purchase agreement and at-the-market offerings in 2024, as well as equity agreements with Gilead Sciences, Inc.
Why It Matters
This filing provides investors with a comprehensive overview of Assembly Biosciences' financial health, strategic activities, and potential risks for the 2024 fiscal year, including significant partnerships.
Risk Assessment
Risk Level: medium — The company operates in the pharmaceutical sector, which is inherently high-risk due to R&D costs, regulatory hurdles, and market competition.
Key Numbers
- 2834 — SIC Code (Indicates the company operates in Pharmaceutical Preparations)
Key Players & Entities
- Assembly Biosciences, Inc. (company) — Filer of the 10-K
- Ventrus Biosciences Inc. (company) — Former name of Assembly Biosciences
- Gilead Sciences, Inc. (company) — Party to equity agreements
- 2024-12-31 (date) — Fiscal year end
- 20250320 (date) — Filing date
FAQ
What were the key financial results for Assembly Biosciences in fiscal year 2024?
The provided text is an excerpt from the 10-K header and does not contain specific financial results for fiscal year 2024. A full review of the filing document is required for this information.
What is the nature of the 'microbiome purchase agreement' mentioned?
The filing indicates 'asmb:MicrobiomePurchaseAgreementMember' as a relevant item for the period 2024-01-01 to 2024-12-31, but the specific terms and details of the agreement are not provided in this excerpt.
What are the 'at-the-market offerings' that occurred in 2024?
The filing references 'asmb:TwoThousandAndTwentyFourAtTheMarketOfferingsMember' for the period 2024-01-01 to 2024-12-31. Further details on the volume and proceeds of these offerings would be in the full filing.
What is the significance of the equity agreements with Gilead Sciences, Inc.?
The filing lists 'asmb:EquityAgreementsMember' involving 'asmb:GileadSciencesIncorporatedMember' and 'us-gaap:CommonStockMember'. The specific details and implications of these agreements are not elaborated in this excerpt.
When did Assembly Biosciences change its name from Ventrus Biosciences Inc.?
The filing states the 'DATE OF NAME CHANGE' from 'VENTRUS BIOSCIENCES INC' to 'ASSEMBLY BIOSCIENCES, INC.' was '20080211'.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 20, 2025 regarding ASSEMBLY BIOSCIENCES, INC. (ASMB).